
CLAIMS


1. Use of a compound in the manufacture of a medicament for the treatment and/or prevention of a Notch dependent cancer wherein said compound having Notch signalling pathway inhibition properties is selected from the group consisting of:

6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of formula I




Formula I

4-(4-cyclohexylphenoxy)aniline of formula III a,




Formula III a

6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine of formula IVa,




Formula IV a

6-(3-(tert-butyl)phenoxy)pyridin-3-amine of formula IIe




Formula II e

4-(4-(tert-butyl)phenoxy)-3-fluoroaniline of formula IIf




Formula II f

6-(4-(tert-Pentyl)phenoxy)pyridin-3-amine of formula IIg,




Formula II g

6-(4-Butylphenoxy)pyridin-3-amine of formula IIh,




Formula II h

3-Fluoro-4-(4-(tert-pentyl)phenoxy)aniline of formula II i,




Formula II i

4-(4-Cyclohexylphenoxy)-3-fluoroaniline of formula III b




Formula III b

4-(4-((3r,5r,7r)-Adamantan-1-yl)phenoxy)aniline of formula IVb



Formula IV b

6-(4-cyclohexylphenoxy)pyridin-3-amine of formula IIIc,



Formula III c

or one of its salts, solvates, tautomers, or isomers thereof.


2. The use of claim 1 wherein the Notch dependent cancer is selected from the group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, and colorectal cancer.

3. The use of claim 1 or 2 wherein the Notch dependent cancer is resistant to γ-secretase inhibitor treatment.

4. The use of any one of claims 1 to 3, wherein the Notch signalling pathway inhibition properties in cancer cells is determined by an *in vitro* γ-secretase complex activity assay.


5. Use of a compound in the manufacture of a pharmaceutical composition for the treatment and/or prevention of a Notch dependent cancer wherein said compound having Notch signalling pathway inhibition properties is selected from the group consisting of:

6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of formula I




Formula I

4-(4-cyclohexylphenoxy)aniline of formula IIIa,




Formula III a

6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine of formula IVa,




Formula IV a

6-(3-(tert-butyl)phenoxy)pyridin-3-amine of formula IIe




Formula II e

4-(4-(tert-butyl)phenoxy)-3-fluoroaniline of formula IIf




Formula II f

6-(4-(tert-Pentyl)phenoxy)pyridin-3-amine of formula IIg,




Formula II g

6-(4-Butylphenoxy)pyridin-3-amine of formula IIh,




Formula II h

3-Fluoro-4-(4-(tert-pentyl)phenoxy)aniline of formula II i,




Formula II i

4-(4-Cyclohexylphenoxy)-3-fluoroaniline of formula III b




Formula III b

4-(4-((3r,5r,7r)-Adamantan-1-yl)phenoxy)aniline of formula IVb



Formula IV b

6-(4-cyclohexylphenoxy)pyridin-3-amine of formula IIIc,



Formula III c

or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof, and wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

6. The use of any one of the preceding claims, wherein said treatment and/or prevention of a Notch dependent cancer further comprises at least one conventional cancer treatment.

7. The use of claim 6 wherein the conventional cancer treatment is administered before, simultaneously or after the administration of a therapeutically effective amount of a medicament of any one of claims 1 to 4, or the pharmaceutical composition of claim 5.

8. The use of claim 6 or 7, wherein the conventional cancer treatment consists of radiotherapy and/or chemotherapy.

9. The use of any one of the preceding claims, wherein said Notch dependent cancer is associated with constitutive activation of the Notch signalling pathway.

10. The use of any one of the preceding claims, for inhibiting *in vitro* the Notch signalling pathway in cells.


11. The use of claim 10 wherein the cells are cancer cells.

12. A kit for use in the treatment and/or prevention of a Notch dependent cancer, the kit comprising one or more doses of a medicament or pharmaceutical composition of any one of claims 1 to 11, optionally with reagents and/or instructions for use.

13. The kit of claim 12, further comprising one or more doses of a chemotherapeutic agent.

AMENDED CLAIMS

1. A compound for use in the treatment and/or prevention of a Notch dependent cancer wherein said compound having Notch signaling pathway inhibition properties is of formula:



Formula II

where m is an integer selected from 1 to 4;

W is selected from H and halogens; the halogen is selected from F-, Cl-, Br- or I-;


R^1, R^2, R^3 and R^4 are each independently selected from the group consisting of H, isopropyl, tertbutyl, $(CH_2)_nCH_3$; the subscript n is an integer independently selected from 1 to 15;

X is O, NR^7 where is R^7 is H;

Y is N or CH;

Z is $NR^{10}NR^{11}$ where R^{10} and R^{11} is H,

or



Formula III

where m is an integer selected from 1 to 4;

W is selected from H and halogens; the halogen is selected from F-, Cl-, Br- or I-;


R^4 and R^{15} are each independently selected from the group consisting of H, tertbutyl, $(CH_2)_nCH_3$; the subscript n is an integer independently selected from 1 to 15;

X is O, NR^7 where is R^7 is H;

Y is N or CH;

Z is $NR^{10}NR^{11}$ where R^{10} and R^{11} is H,

~~or~~



~~Formula IV~~

~~where m is an integer selected from 1 to 4;~~

~~W is selected from H and halogens; the halogen is selected from F-, Cl-, Br- or I-;~~

~~R^4 is independently selected from the group consisting of H, isopropyl, tertbutyl, $(CH_2)_nCH_3$; the subscript n is an integer independently selected from 1 to 15;~~


~~X is O, NR^7 where is R^7 is H;~~

~~Y is N or CH;~~

~~Z is $NR^{10}NR^{11}$ where R^{10} and R^{11} is H.~~


~~21~~. Use of a compound in the manufacture of a medicament for the treatment and/or prevention of a Notch dependent cancer wherein said compound having Notch signalling pathway inhibition properties ~~The compound according to claim 1 wherein said compound~~ is selected from the group consisting of:

6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of formula I




Formula I

4-(4-cyclohexylphenoxy)aniline of formula IIIa,




Formula III a

6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine of formula IVa,




Formula IV a

6-(3-(tert-butyl)phenoxy)pyridin-3-amine of formula IIe




Formula II e

4-(4-(tert-butyl)phenoxy)-3-fluoroaniline of formula IIf




Formula II f

6-(4-(tert-Pentyl)phenoxy)pyridin-3-amine of formula IIg,




Formula II g

6-(4-Butylphenoxy)pyridin-3-amine of formula IIh,




Formula II h

3-Fluoro-4-(4-(tert-pentyl)phenoxy)aniline of formula II i,




Formula II i

4-(4-Cyclohexylphenoxy)-3-fluoroaniline of formula III b




Formula III b

4-(4-((3r,5r,7r)-Adamantan-1-yl)phenoxy)aniline of formula IVb



Formula IV b

6-(4-cyclohexylphenoxy)pyridin-3-amine of formula IIIc,



Formula III c

or one of its salts, solvates, tautomers, or isomers thereof.


~~3~~2. The ~~compound~~ use of claim 1 ~~or 2~~ wherein the Notch dependent cancer is selected from the group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma (MCL), breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, and colorectal cancer.

~~4~~3. The ~~compound~~ use of ~~anyone of~~ claim~~s~~ 1 ~~3~~ or 2 wherein the Notch dependent cancer is resistant to γ-secretase inhibitor treatment.

4. The use of any one of claims 1 to 3, wherein the Notch signalling pathway inhibition properties in cancer cells is determined by an *in vitro* γ-secretase complex activity assay.


5. Use of a compound in the manufacture of a pharmaceutical composition for the treatment and/or prevention of a Notch dependent cancer wherein said compound having Notch signalling pathway inhibition properties~~A pharmaceutical composition comprising a compound of anyone of claims 1-4~~ is selected from the group consisting of:

6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of formula I




Formula I

4-(4-cyclohexylphenoxy)aniline of formula IIIa,




Formula III a

6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine of formula IVa,




Formula IV a

6-(3-(tert-butyl)phenoxy)pyridin-3-amine of formula IIe




Formula II e

4-(4-(tert-butyl)phenoxy)-3-fluoroaniline of formula IIf




Formula II f

6-(4-(tert-Pentyl)phenoxy)pyridin-3-amine of formula IIg,




Formula II g

6-(4-Butylphenoxy)pyridin-3-amine of formula IIh,




Formula II h

3-Fluoro-4-(4-(tert-pentyl)phenoxy)aniline of formula II i,




Formula II i

4-(4-Cyclohexylphenoxy)-3-fluoroaniline of formula III b




Formula III b

4-(4-((3r,5r,7r)-Adamantan-1-yl)phenoxy)aniline of formula IVb



Formula IV b

6-(4-cyclohexylphenoxy)pyridin-3-amine of formula IIIc,



Formula III c

or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof, and wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

6. The use of any one of the preceding claims, wherein said treatment and/or prevention of a Notch dependent cancer further comprises at least one conventional cancer treatment.

7. The use of claim 6 wherein the conventional cancer treatment is administered before, simultaneously or after the administration of a therapeutically effective amount of a medicament of any one of claims 1 to 4, or the pharmaceutical composition of claim 5.

8. The use of claim 6 or 7, wherein the conventional cancer treatment consists of radiotherapy and/or chemotherapy.

9. The use of any one of the preceding claims, wherein said Notch dependent cancer is associated with constitutive activation of the Notch signalling pathway.

10. The use of any one of the preceding claims, for inhibiting *in vitro* the Notch signalling pathway in cells.

11. The use of claim 10 wherein the cells are cancer cells.

~~6~~12. A kit for use in the treatment and/or prevention of a Notch dependent cancer, the kit comprising one or more doses of a ~~compound~~ medicament or pharmaceutical composition of any one of claims 1 to ~~4~~11, optionally with reagents and/or instructions for use.

~~7~~13. The kit of claim ~~6~~12, further comprising one or more doses of a chemotherapeutic agent.

~~8. Use of a compound of anyone of claims 1-4, for inhibiting *in vitro* the Notch signalling pathway in cells.~~

~~9. The use of claim 8 wherein the cells are cancer cells.~~

10. Use of a compound of anyone of claims 1-4, for inhibiting *in vivo* the Notch signalling pathway in cells.

11. The use of claim 10 wherein the cells are cancer cells.

12. A method of treating a subject for Notch dependent cancer, comprising

i) determining in cancer cells obtained from a biological sample of said subject whether the cancer is Notch signalling pathway dependent,

ii) and treating said subject based upon whether the cancer is Notch dependent cancer by administering a therapeutically effective amount of a compound of anyone of claims 1-4, or a
pharmaceutical composition of claim 5.

13. The method of treating of claim 12 wherein the Notch signalling pathway dependency in cancer cells is determined by an *in vitro* γ-secretase complex activity assay.

14. The method of treating of claim 12 or 13 further comprising administering at least one conventional cancer treatment.

15. The method of treating of claim 13 wherein the conventional cancer treatment is administered before, simultaneously or after the administration of the therapeutically effective amount of a compound of anyone of claims 1-4, or the pharmaceutical composition of claim 5.

16. The method of treating of claim 14 or 15 wherein the conventional cancer treatment consists in radiotherapy and/or chemotherapy.

17. A method of treatment of a disease associated with an up-regulated Notch signalling pathway activity, comprising administrating a compound of anyone of claims 1-4, or the pharmaceutical composition of claim 5 to a subject in need thereof.